Latest post

Phase 1 trial showed THR-149 is a highly potent plasma kallikrein inhibitor to treat DME

In 2019, Oxurion announced positive topline data for the compound THR-149, a highly potent plasma kallikrein inhibitor to treat diabetic macular edema (DME).

back of the eye diseases, science community,

Positive phase 1 data indicate THR-687 could be an effective therapy for patients with DME

Oxurion kick-started 2020 with positive topline data from phase 1 clinical trial evaluating THR-687 for treatment of DME.